<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of primary prevention implantable cardioverter-defibrillator (ICD) trials</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of primary prevention implantable cardioverter-defibrillator (ICD) trials</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of primary prevention implantable cardioverter-defibrillator (ICD) trials</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Trial</td> <td class="subtitle1">Enrollment/follow-up</td> <td class="subtitle1">Number of patients</td> <td class="subtitle1">Ischemic/non-ischemic CMP</td> <td class="subtitle1">Entry criteria</td> <td class="subtitle1">Medical therapies?</td> <td class="subtitle1">Outcomes with ICD</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Ischemic CMP (late post-MI) trials</td> </tr> <tr> <td class="indent1">MADIT-I</td> <td>1991 to 1996<br/> Mean follow-up 27 months</td> <td class="centered">196</td> <td class="centered">100%/0%</td> <td> <ul> <li>Prior MI </li> <li>NSVT on ECG monitoring </li> <li>LVEF ≤35% </li> <li>NYHA I/II/III </li> <li>Inducible VT during EPS </li> </ul> </td> <td> <ul> <li>BB - 17% </li> <li>ACE/ARB - 58% </li> <li>MRA - NR </li> <li>AAD - 60% </li> </ul> </td> <td>Total mortality: HR 0.46 (95% CI 0.26-0.82) compared with conventional medical therapy alone</td> </tr> <tr> <td class="indent1">MUSTT</td> <td>1990 to 1996<br/> Mean follow-up 39 months</td> <td class="centered">704</td> <td class="centered">100%/0%</td> <td> <ul> <li>Prior MI </li> <li>NSVT on ECG monitoring </li> <li>LVEF ≤40% </li> <li>NYHA I/II/III </li> <li>Inducible VT during EPS </li> </ul> </td> <td> <ul> <li>BB - 40% </li> <li>ACE/ARB - 75% </li> <li>MRA - NR </li> <li>AAD - 45% </li> </ul> </td> <td>SCA or death from arrhythmia: RR 0.24 (95% CI 0.13-0.45) for ICD versus no ICD</td> </tr> <tr> <td class="indent1">CABG-Patch</td> <td>1993 to 1996<br/> Mean follow-up 32 months</td> <td class="centered">900</td> <td class="centered">100%/0%</td> <td> <ul> <li>&lt;80 years old </li> <li>Scheduled for elective CABG </li> <li>LVEF &lt;36% </li> <li>Abnormal SAECG </li> </ul> </td> <td> <ul> <li>BB - 21% </li> <li>ACE-I - 54% </li> <li>MRA - NR </li> <li>AAD - NR </li> </ul> </td> <td>Death from any cause: HR 1.07 (95% CI 0.81-1.42) ICD versus control*</td> </tr> <tr class="divider_bottom"> <td class="indent1">MADIT-II</td> <td>1997 to 2001<br/> Mean follow-up 20 months</td> <td class="centered">1232</td> <td class="centered">100%/0%</td> <td> <ul> <li>Prior MI </li> <li>LVEF ≤35% </li> <li>NYHA I/II/III<sup>¶</sup> </li> </ul> </td> <td> <ul> <li>BB - 70% </li> <li>ACE/ARB - 70% </li> <li>MRA - NR </li> <li>AAD - 14% </li> </ul> </td> <td>Total mortality: HR 0.65 (95% CI 0.51-0.93) compared with conventional medical therapy alone</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Ischemic CMP (early post-MI) trials</td> </tr> <tr> <td class="indent1">DINAMIT</td> <td>1998 to 2003<br/> Mean follow-up 30 months</td> <td class="centered">674</td> <td class="centered">100%/0%</td> <td> <ul> <li>6 to 40 days post-MI </li> <li>LVEF ≤35% </li> <li>Impaired autonomic function (depressed HR variability or elevated average 24-hour HR on Holter monitoring) </li> </ul> </td> <td> <ul> <li>BB - 87% </li> <li>ACE-I - 95% </li> <li>MRA - NR </li> <li>AAD - 11% </li> </ul> </td> <td>Total mortality: HR 1.08 (95% CI 0.76-1.55), ICD versus control group</td> </tr> <tr class="divider_bottom"> <td class="indent1">IRIS</td> <td>1999 to 2007<br/> Mean follow-up 37 months</td> <td class="centered">898</td> <td class="centered">100%/0%</td> <td> <ul> <li>5 to 31 days post-MI </li> <li>LVEF ≤40% and HR ≥90 BPM on first ECG or NSVT </li> </ul> </td> <td> <ul> <li>BB - 87% </li> <li>ACE-I - 82% </li> <li>MRA - NR </li> <li>AAD - NR </li> </ul> </td> <td>Total mortality: HR 1.04 (95% CI 0.81-1.35) ICD versus control group</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Combined ischemic and nonischemic CMP trial</td> </tr> <tr class="divider_bottom"> <td class="indent1">SCD-HeFT</td> <td>1997 to 2003<br/> Mean follow-up 45 months</td> <td class="centered">2521</td> <td class="centered">52%/48%</td> <td> <ul> <li>HF for ≥3 months </li> <li>LVEF ≤35% </li> <li>NYHA II/III </li> </ul> </td> <td> <ul> <li>BB - 69% </li> <li>ACE/ARB - 85% </li> <li>MRA - NR </li> <li>AAD - 34% randomized to amiodarone; additional 7% crossover to amiodarone </li> </ul> </td> <td>Total mortality: HR 0.77 (95% CI 0.62-0.96) compared with conventional medical therapy alone</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Nonischemic CMP trials</td> </tr> <tr> <td class="indent1">DEFINITE</td> <td>1998 to 2003<br/> Mean follow-up 29 months</td> <td class="centered">458</td> <td class="centered">0%/100%</td> <td> <ul> <li>Nonischemic CMP </li> <li>LVEF ≤35% </li> <li>NYHA I/II/III </li> <li>PVCs or NSVT </li> </ul> </td> <td> <ul> <li>BB - 85% </li> <li>ACE/ARB - 97% </li> <li>MRA - NR </li> <li>AAD - 5% </li> </ul> </td> <td>Total mortality: HR 0.65 (95% CI 0.4-1.06) compared with conventional medical therapy alone</td> </tr> <tr> <td class="indent1">COMPANION</td> <td>2000 to 2002<br/> Median follow-up of 16 months</td> <td class="centered">1520</td> <td class="centered">55%/45%</td> <td> <ul> <li>LVEF ≤35% </li> <li>NYHA III/IV requiring hospitalization within prior year </li> </ul> </td> <td> <ul> <li>BB - 67% </li> <li>ACE/ARB - 69% </li> <li>MRA - 55% </li> <li>AAD - NR </li> </ul> </td> <td>Combined HF death or HF hospitalization: HR 0.68 (95% CI 0.68-0.95) for CRT versus medical therapy alone</td> </tr> <tr> <td class="indent1">DANISH</td> <td>2008 to 2014<br/> Mean follow-up 68 months</td> <td class="centered">1114</td> <td class="centered">0%/100%</td> <td> <ul> <li>Nonischemic CMP </li> <li>LVEF ≤35% </li> <li>NYHA II/III (or IV if CRT planned) </li> </ul> </td> <td> <ul> <li>BB - 92% </li> <li>ACE/ARB - 97% </li> <li>MRA - 58% </li> <li>CRT - 58% </li> <li>AAD - 6% </li> </ul> </td> <td>Total mortality: HR 0.87 (95% CI 0.68-1.12) compared with conventional HF therapy alone</td> </tr> </tbody></table></div><div class="graphic_footnotes">AAD: antiarrhythmic drugs; ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; BB: beta blocker; BPM: beats per minute; CABG: coronary artery bypass graft surgery; CMP: cardiomyopathy; CRT: cardiac resynchronization therapy; HF: heart failure; ECG: electrocardiogram; EPS: electrophysiologic study; ICD: implantable cardioverter-defibrillator; LVEF: left ventricular ejection fraction; MI: myocardial infarction; MRA: mineralocorticoid receptor antagonist; NR: not reported (likely near zero given early date of trial); NSVT: nonsustained ventricular tachycardia; NYHA: New York Heart Association; PVC: premature ventricular contraction; SAECG: signal averaged electrocardiogram; SCA: sudden cardiac arrest; VT: ventricular tachycardia.<br/>* Epicardial ICDs were predominantly used in the CABG Patch trial, as patients were all undergoing CABG. This is not consistent with contemporary practice.<br/>¶ Some patients with NYHA class IV functional status were enrolled in MADIT-II, but the requirement was to be NYHA class I/II/III at the time of enrollment.</div><div id="graphicVersion">Graphic 98261 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
